Tong et al developed a prognostic model for patients with hypocellular myelodysplastic syndrome. This can help to identify patients who may require more aggressive management. The authors are from the University of Texas M.D. Anderson Cancer Center in Houston.
Patient selection: hypocellular myelodysplastic syndrome (bone marrow cellularity < 20%)
Parameters:
(1) hemoglobin in g/dL
(2) ECOG performance status
(3) unfavorable cytogenetics
(4) percent blasts in the bone marrow
(5) serum LDH in IU/L
|
Parameter |
Finding |
Points |
|
hemoglobin |
>= 10 g/dL |
0 |
|
|
< 10 g/dL |
1 |
|
ECOG performance status |
0 or 1 |
0 |
|
|
2 to 4 |
1 |
|
cytogenetics |
absent |
0 |
|
|
present (complex or -7/-7q) |
1 |
|
percent bone marrow blasts |
< 5% |
0 |
|
|
>= 5% |
1 |
|
serum LDH |
<= 600 IU/L |
0 |
|
|
> 600 IU/L |
1 |
where:
• The gender was not used to qualify hemoglobin levels.
• The method and reference range for serum LDH not given.
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the worse the prognosis.
|
Total Score |
Risk Group |
Median Survival |
|
0 |
low |
not reached |
|
1 |
low |
27 months |
|
2 |
intermediate |
19 months |
|
3 |
high |
9 months |
|
4 |
high |
5 months |
|
5 |
high |
2 months |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
